Datum Källa Rubrik Typ Alternativ
2024-05-24 Iconovo ICONOVO AB PUBLISHES THE ANNUAL REPORT 2023 IN ENGLISH Rapporter Ladda ner | Visa Stäng
2024-05-21 Iconovo Kommuniké från årsstämma i Iconovo AB den 21 maj 2024 Pressreleaser Ladda ner | Visa Stäng
2024-05-21 Iconovo BioStock: Iconovo initiates development of inhaled obesity treatment Pressreleaser Visa Stäng
2024-05-21 Iconovo BioStock: Iconovo inleder utveckling av inhalerad fetmabehandling Pressreleaser Visa Stäng
2024-05-15 Iconovo Iconovo files patent application for inhaled GLP-1 products and initiates development of new obesity treatments Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 15 May 2024 | Iconovo

Iconovo files patent application for inhaled GLP-1 products and initiates development of new obesity treatments

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the company has filed a broad patent application related to inhaled GLP-1 receptor agonists. This marks the first step in Iconovo’s new initiative to develop more convenient, reliable, and cost-effective treatments for obesity. Based on its proprietary inhalers, the company aims to license out selected products after the preclinical proof-of-concept stage. Inhaled GLP-1 addresses a rapidly growing market, expected to reach USD 90 billion in 2029.

The inhaled GLP-1 products will be developed in Iconovo’s proprietary inhalers, primarily as a treatment for obesity with the opportunity to include other metabolic diseases like type 2 diabetes, fatty liver disease, cardiovascular disease and sleep apnea. The investments required in the initial development phase are limited.

“As a leading inhalation company, with a range of fully developed inhaler platforms and the competence to formulate pharmaceutical compounds into powders, we are in a perfect position to take a step into reformulation of selected high-value products in areas where inhalation can offer significant patient benefits. We are very excited to take this important step towards the development of a next generation of patient-friendly GLP-1 treatments with sustained efficacy”, says Johan Wäborg, CEO of Iconovo.

Most of today’s GLP-1 treatments, like Zepbound® (Eli Lilly) and Wegovy® (Novo Nordisk), are administered via subcutaneous injection, which is considered both stress- and painful by many patients. Iconovo’s inhaled treatments would give patients access to an alternative that is pain-free, and much more convenient. Since it is not an injection, there would be no requirements for cold storage to ensure the treatment’s durability, making inhaled treatment more reliable and cost-effective.

At present there is one oral GLP-1 treatment on the market, and more are under development. So far, bioavailability has been a major challenge with only about 1% of the active drug reaching its target. Iconovo estimates that inhaled GLP-1 would reach efficacy levels comparable to injected treatments, making it potentially competitively advantageous to oral treatments.

The patent application for inhaled GLP-1 receptor agonists addresses a very large and rapidly growing market presently worth USD 35 billion with an expectancy to grow at an annual rate of 17% to USD 90 billion in 2029. (Source: GlobalData).

2024-05-15 Iconovo Iconovo lämnar in patentansökan för inhalerade GLP-1-produkter och inleder utveckling av nya fetmabehandlingar Pressreleaser Ladda ner | Visa Stäng
2024-05-06 Iconovo Iconovo receives patent protection for ICOres® in China Pressreleaser Ladda ner | Visa Stäng
2024-05-06 Iconovo Iconovo erhåller patentskydd för ICOres® i Kina Pressreleaser Ladda ner | Visa Stäng
2024-04-26 Penser Access by Carnegie Penser Access by Carnegie: Intervju med Iconovo - Carnegie Investment Bank - 26 april 2024 Pressreleaser Visa Stäng
2024-04-26 Penser Access by Carnegie Penser Access by Carnegie: Iconovo - Rapport utan överraskningar Pressreleaser Visa Stäng
2024-04-26 Redeye Redeye: Iconovo Q1 - Solid quarter with a near-term catalyst on the horizon Pressreleaser Ladda ner | Visa Stäng
2024-04-25 Iconovo QUARTERLY REPORT Rapporter Ladda ner | Visa Stäng
2024-04-25 Iconovo KVARTALSRAPPORT Rapporter Ladda ner | Visa Stäng
2024-04-25 Iconovo ICONOVO AB PUBLICERAR ÅRSREDOVISNING FÖR 2023 Rapporter Ladda ner | Visa Stäng
2024-04-19 Iconovo Kallelse till årsstämma i Iconovo AB Pressreleaser Ladda ner | Visa Stäng
2024-03-20 Penser Access by Carnegie Penser Access by Carnegie: Iconovo - En ljus framtid Pressreleaser Visa Stäng
2024-03-11 Iconovo Iconovo presenterar positiva data från en feasibility-studie med Nanofitins® i ICOone® Pressreleaser Ladda ner | Visa Stäng
2024-03-11 Iconovo Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone® Pressreleaser Ladda ner | Visa Stäng
2024-03-06 Iconovo Kommuniké från extra bolagsstämma i Iconovo AB den 6 mars 2024 Pressreleaser Ladda ner | Visa Stäng
2024-03-05 Iconovo Iconovo erhåller anslag om SEK 680 000 från Innowwide för satsning på den Sydkoreanska marknaden Pressreleaser Ladda ner | Visa Stäng
2024-03-05 Iconovo Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea Pressreleaser Ladda ner | Visa Stäng
2024-02-19 Redeye Redeye: Iconovo Q4 - Aligned with our expectations and a directed issue announcement Pressreleaser Ladda ner | Visa Stäng
2024-02-15 Iconovo KALLELSE TILL EXTRA BOLAGSSTÄMMA I ICONOVO AB Pressreleaser Ladda ner | Visa Stäng
2024-02-15 Iconovo KVARTALSRAPPORT Rapporter Ladda ner | Visa Stäng
2024-02-15 Iconovo QUARTERLY REPORT Rapporter Ladda ner | Visa Stäng
2024-02-15 Iconovo Iconovo genomför riktad nyemission om 33,3 MSEK, delvis villkorad av efterföljande godkännande från extra bolagsstämma och tidigarelägger offentliggörande av bokslutskommunikén Pressreleaser Ladda ner | Visa Stäng
2024-02-15 Iconovo Iconovo carries out a directed share issue of SEK 33.3 million, partly subject to subsequent approval by the Extraordinary General Meeting, and brings forward the publication of the year-end report Pressreleaser Ladda ner | Visa Stäng
2024-02-12 Iconovo BioStock: Iconovo inleder 2024 med order från ledande läkemedelsbolag Pressreleaser Visa Stäng
2024-02-07 Iconovo Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease Pressreleaser Ladda ner | Visa Stäng
2024-02-07 Iconovo Iconovo tecknar ytterligare avtal med Kiox Pharma för utveckling av en ny inhalerbar behandling av interstitiell lungsjukdom Pressreleaser Ladda ner | Visa Stäng
2024-02-06 Iconovo Iconovo launches improved versions of nasal ICOone® inhalers Pressreleaser Ladda ner | Visa Stäng
2024-02-06 Iconovo Iconovo lanserar förbättrade versioner av nasala ICOone® inhalator Pressreleaser Ladda ner | Visa Stäng
2024-02-01 Iconovo Iconovo receives order from Top-10 Pharma company for evaluation of multi-dose inhaler Pressreleaser Ladda ner | Visa Stäng
2024-02-01 Iconovo Iconovo erhåller order från Top-10 Pharma-bolag för utvärdering av flerdosinhalator Pressreleaser Ladda ner | Visa Stäng
2024-01-08 Iconovo Iconovo recruits Gary Pitcairn (PhD) as Senior Scientific Advisor Pressreleaser Ladda ner | Visa Stäng
2024-01-08 Iconovo Iconovo rekryterar Gary Pitcairn (PhD) som Senior Scientific Advisor Pressreleaser Ladda ner | Visa Stäng
2023-12-22 Iconovo Iconovos vd till BioStock: "Vi siktar på en affär för ICOpre under 2024" Pressreleaser Visa Stäng
2023-12-06 Redeye Redeye: Redeye Initiates Coverage of Iconovo Pressreleaser Ladda ner | Visa Stäng
2023-11-30 Iconovo Iconovo AB byter likviditetsgarant och Certified Adviser till Carnegie Investment Bank AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-11-30 Iconovo Iconovo AB changes liquidity provider and Certified Adviser to Carnegie Investment Bank AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-11-29 Iconovo Valberedning utsedd Iconovo AB Pressreleaser Ladda ner | Visa Stäng
2023-11-29 Iconovo Nomination Committee appointed at Iconovo AB Pressreleaser Ladda ner | Visa Stäng
2023-11-20 Iconovo BioStock: Hektiska dagar för Iconovo på BIO-Europe Pressreleaser Visa Stäng
2023-11-20 Iconovo BioStock: Busy days for Iconovo at BIO-Europe Pressreleaser Visa Stäng
2023-11-16 Iconovo Iconovo and Arcede Pharma take the next step in the development of a new treatment for COPD Pressreleaser Ladda ner | Visa Stäng
2023-11-16 Iconovo Iconovo och Arcede Pharma tar nästa steg i utvecklingen av en ny behandling mot KOL Pressreleaser Ladda ner | Visa Stäng
2023-10-31 Iconovo Iconovos styrelseledamot och medgrundare Mats Johansson förvärvar aktier för 2 039 388 SEK Pressreleaser Ladda ner | Visa Stäng
2023-10-30 Penser Access Penser Access: Q3’23 - Iconovo Pressreleaser Visa Stäng
2023-10-27 Iconovo Kommuniké från extra bolagsstämma i Iconovo AB den 27 oktober 2023 Pressreleaser Ladda ner | Visa Stäng
2023-10-27 Iconovo QUARTERLY REPORT Rapporter Ladda ner | Visa Stäng
2023-10-27 Iconovo KVARTALSRAPPORT Rapporter Ladda ner | Visa Stäng
2023-10-17 Iconovo Iconovos styrelse kommenterar att företagets vd åtalats för misstänkt marknadsmanipulation i annat bolags aktie Pressreleaser Ladda ner | Visa Stäng
2023-10-09 Iconovo BioStock: Iconovo välkomnar Gerald Engström som huvudägare genom nyemission Pressreleaser Visa Stäng
2023-10-09 Iconovo BioStock: Iconovo welcomes Gerald Engström as largest shareholder through share issue Pressreleaser Visa Stäng
2023-09-27 Iconovo BioStock Investor Meeting: Iconovo Pressreleaser Visa Stäng
2023-09-27 Iconovo BioStock Investor Meeting: Iconovo Pressreleaser Visa Stäng
2023-09-26 Iconovo KALLELSE TILL EXTRA BOLAGSSTÄMMA I ICONOVO AB Pressreleaser Ladda ner | Visa Stäng
2023-09-26 Iconovo Iconovo genomför riktad nyemission om cirka 19,2 MSEK Pressreleaser Ladda ner | Visa Stäng
2023-09-26 Iconovo Iconovo carries out a directed share issue of approx. SEK 19.2 million Pressreleaser Ladda ner | Visa Stäng
2023-09-26 Iconovo Iconovos partner Monash University har slutfört rekryteringen till en klinisk fas I-studie av inhalerat oxytocin i ICOone® Pressreleaser Ladda ner | Visa Stäng
2023-09-26 Iconovo Iconovo's partner Monash University has completed enrollment in a Phase I clinical trial of inhaled oxytocin in ICOone® Pressreleaser Ladda ner | Visa Stäng
2023-09-19 Iconovo Iconovo beviljas ett amerikanskt patent för ICOcap® som stärker erbjudandet för att nå fler kundsamarbeten Pressreleaser Ladda ner | Visa Stäng
2023-09-19 Iconovo Iconovo receives a US patent for ICOcap® that strengthens the offering for more customer collaborations Pressreleaser Ladda ner | Visa Stäng
2023-09-18 Iconovo BioStock: Iconovo gör framsteg i utlicenseringsprocessen för ICOpre Pressreleaser Visa Stäng
2023-09-18 Iconovo BioStock: Iconovo makes progress in the outlicensing process for ICOpre Pressreleaser Visa Stäng
2023-09-13 Iconovo Iconovo launches the outreach phase in the structured process for out-licensing of ICOpre Pressreleaser Ladda ner | Visa Stäng
2023-09-13 Iconovo Iconovo inleder kontaktfasen i den strukturerade processen för att utlicensiera ICOpre Pressreleaser Ladda ner | Visa Stäng
2023-08-30 Iconovo Iconovos ny styrelseledamot förvärvar aktier för 204 373 SEK Pressreleaser Ladda ner | Visa Stäng
2023-08-29 Iconovo Kommuniké från extra bolagsstämma i Iconovo AB den 28 augusti 2023 Pressreleaser Ladda ner | Visa Stäng
2023-08-23 Iconovo BioStock: Iconovo on the way to profitability Pressreleaser Visa Stäng
2023-08-23 Iconovo BioStock: Iconovo om vägen till lönsamhet Pressreleaser Visa Stäng
2023-08-22 Iconovo Iconovo strengthens patent protection for ICOres® in the EU Pressreleaser Ladda ner | Visa Stäng
2023-08-22 Iconovo Iconovo stärker patentskyddet för ICOres® i EU Pressreleaser Ladda ner | Visa Stäng
2023-08-17 Iconovo Iconovo receives additional development contract from Kiox Pharma for new inhalable treatment against rare disease Pressreleaser Ladda ner | Visa Stäng
2023-08-17 Iconovo Iconovo får ytterligare utvecklingsuppdrag av Kiox Pharma gällande ny inhalerbar behandling mot sällsynt sjukdom Pressreleaser Ladda ner | Visa Stäng
2023-08-16 Iconovo Iconovo befäster sina långsiktiga finansiella mål för 2027, förväntad helårslönsamhet 2026 Pressreleaser Ladda ner | Visa Stäng
2023-08-16 Iconovo Iconovo confirms its long-term financial targets for 2027 with expected full-year profitability in 2026 Pressreleaser Ladda ner | Visa Stäng
2023-08-09 Iconovo KALLELSE TILL EXTRA BOLAGSSTÄMMA I ICONOVO AB Pressreleaser Ladda ner | Visa Stäng
2023-07-17 Penser Access Penser Access: Q2 2023 - Iconovo Pressreleaser Visa Stäng
2023-07-14 Penser Access Penser Access: Intervju med Iconovo - Erik Penser Bank - 14 juli 2023 Pressreleaser Visa Stäng
2023-07-14 Iconovo KVARTALSRAPPORT, Q2 2023 Rapporter Ladda ner | Visa Stäng
2023-07-13 Iconovo Iconovo ökar försäljningsinsatserna och säkrar produktionen för ICOcap genom omstrukturerat avtal med Stevanato Pressreleaser Ladda ner | Visa Stäng
2023-07-13 Iconovo Iconovo increases sales efforts and supply chain security for ICOcap through restructured agreement with Stevanato Pressreleaser Ladda ner | Visa Stäng
2023-06-22 Iconovo BioStock: Iconovo ingår samarbete med Affilogic Pressreleaser Visa Stäng
2023-06-22 Iconovo BioStock: Iconovo initiates collaboration with Affilogic Pressreleaser Visa Stäng
2023-06-19 Iconovo Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies Pressreleaser Ladda ner | Visa Stäng
2023-06-19 Iconovo Iconovo inleder feasibility-studie med Affilogic för utveckling av inhalerbara Nanofitin®-baserade bioterapier Pressreleaser Ladda ner | Visa Stäng
2023-06-15 Iconovo BioStock: Iconovo launch Accelerator Program Pressreleaser Visa Stäng
2023-06-15 Iconovo BioStock: Iconovo lanserar Accelerator Program Pressreleaser Visa Stäng
2023-06-09 Iconovo Iconovo inleder samarbete med danskt mindre bolag om utveckling av en ny inhalerbar behandling mot sällsynt sjukdom Pressreleaser Ladda ner | Visa Stäng
2023-06-09 Iconovo Iconovo initiates collaboration with a small Danish company to develop a new inhalable treatment for a rare disease Pressreleaser Ladda ner | Visa Stäng
2023-06-01 Iconovo Iconovo ökar möjligheterna för kunder inom affärsområdet originalläkemedel att finansiera innovativa utvecklingsprojekt Pressreleaser Ladda ner | Visa Stäng
2023-06-01 Iconovo Iconovo provides increased opportunities for customers in its Novel Pharmaceuticals business segment to finance innovative development projects Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

12 Jul 2024 | Kvartalsrapport 2024-Q2
24 Oct 2024 | Kvartalsrapport 2024-Q3